Skip to main content

Table 4 Intermediate and cumulative system effectiveness for the delivery of IPTp with and without directly observed therapy (DOT) through the antenatal care platform

From: Effectiveness of the delivery of interventions to prevent malaria in pregnancy in Kenya

  Level 4 Levels 3 and 2
n Intermediate Cumulative n Intermediate Cumulative
% (95 % CI) % (95 % CI) % (95 % CI) % (95 % CI)
With DOT  
 IPTp eligiblea 304    242   
 SP in stock 304 100.0 100.0 242 100.0 100.0
 Receive SP during visit 208 68.6 [60.2, 75.9] 68.6 [60.2, 75.9] 198 80.3 [61.7, 91.1] 80.3 [61.7, 91.1]
 Receive three doses SP during visit 206 99.0 [96.1, 99.7] 67.8 [60.6, 74.3] 187 94.1 [77.5, 98.7] 75.5 [55.4, 88.5]
 Took SP by DOT 121 64.6 [22.2, 92.1] 39.8 [12.5, 75.4] 129 70.1 [22.1, 95.1] 53.3 [21.0, 83.1]
With or without DOTb  
 IPTp eligiblea 208    220   
 SP in stock 208 100.0 100.0 220 100.0 100.0
 Being given SP during visit 140 67.5 [60.3, 74.0] 67.5 [60.3, 74.0] 181 79.7 [60.8, 90.9] 79.7 [60.8, 90.9]
 Being given three doses SP during visit 139 99.2 [96.2, 99.9] 67.0 [60.6, 72.8] 170 93.4 [74.5, 98.6] 74.5 [53.6, 88.1]
 Has SP on exit 52 88.0 [63.3, 96.9] 40.3 [18.2, 67.2] 50 93.4 [45.9, 99.6] 54.0 [17.6, 86.5]
 Knows to take three tablets SP 48 92.1 [78.1, 97.5] 37.2 [17.7, 61.9] 49 96.4 [59.6, 99.8] 52.5 [16.3, 86.2]
 SP by DOT 80 58.3 [19.3, 89.1] 39.1 [15.9, 68.6] 118 71.0 [22.9, 95.3] 52.9 [20.2, 83.2]
 Knows to take three tablets SP or took SP as DOT 128 92.1 [87.4, 95.1] 61.7 [55.7, 67.4] 167 97.1 [70.6, 99.8] 72.3 [46.9, 88.6]
  1. aIPTp eligibility according to Kenya national guidelines was women not taking cotrimoxazole (or being HIV positive as a proxy for cotrimoxazole use), having felt the baby move (i.e. past quickening) or being 16 weeks gestation or over
  2. bAnalysis limited to participants completing exit interviews where information on availability of SP at exit was collected
  3. ANC antenatal care; CI confidence interval, DOT directly observed therapy, IPTp intermittent preventive treatment SP sulfadoxine–pyrimethamine